BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26893272)

  • 21. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
    Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
    In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
    Baud M; Strano S; Dechartres A; Jouni R; Triponez F; Chouaid C; Forgez P; Damotte D; Roche N; Régnard JF; Alifano M
    J Thorac Cardiovasc Surg; 2013 May; 145(5):1305-11. PubMed ID: 23072703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
    Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
    Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for 100 patients with malignant pleural mesothelioma.
    Gonlugur U; Gonlugur TE
    Arch Environ Occup Health; 2010; 65(2):65-9. PubMed ID: 20439224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
    Berardi R; Caramanti M; Fiordoliva I; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Castagnani M; Rovinelli F; Onofri A; Cascinu S
    Support Care Cancer; 2015 Mar; 23(3):621-6. PubMed ID: 25142706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Grover S; Friedberg JS; Simone CB
    J Thorac Cardiovasc Surg; 2019 Feb; 157(2):758-766.e1. PubMed ID: 30454981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
    Kaya H; Sezgı C; Tanrıkulu AC; Taylan M; Abakay O; Sen HS; Abakay A; Kucukoner M; Kapan M
    Neoplasma; 2014; 61(4):433-8. PubMed ID: 24645844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
    Fusco V; Ardizzoni A; Merlo F; Cinquegrana A; Faravelli B; De Palma M; Chessa L; Nicolò G; Serra M; Capaccio A
    Anticancer Res; 1993; 13(3):683-9. PubMed ID: 8317897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.
    Hysi I; Le Pimpec-Barthes F; Alifano M; Venissac N; Mouroux J; Regnard JF; Riquet M; Porte H
    Oncol Rep; 2014 Jan; 31(1):415-21. PubMed ID: 24142233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.
    Wang S; Ma K; Chen Z; Yang X; Sun F; Jin Y; Shi Y; Jiang W; Wang Q; Zhan C
    World J Surg; 2018 Jul; 42(7):2134-2142. PubMed ID: 29282508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
    Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
    PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
    Baldini EH; Richards WG; Gill RR; Goodman BM; Winfrey OK; Eisen HM; Mak RH; Chen AB; Kozono DE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2015 May; 149(5):1374-81. PubMed ID: 25772281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
    Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
    Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
    Kataoka Y; Yamamoto Y; Otsuki T; Kaku S; Maehashi-Wada N; Fukuma S; Hirabayashi M; Nakano T; Fukuhara S
    Lung Cancer; 2017 Nov; 113():88-92. PubMed ID: 29110856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
    Taioli E; Wolf AS; Camacho-Rivera M; Kaufman A; Lee DS; Nicastri D; Rosenzweig K; Flores RM
    PLoS One; 2015; 10(12):e0145039. PubMed ID: 26660351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
    Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
    BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.